Claims for Patent: 8,435,951

Summary for Patent: 8,435,951

Title:	Treating neoplasms with neurotoxin
Abstract:	The present invention provides a method of treating a cancer using a neurotoxin, preferably Botulinum toxin (\"BTX\"). The application of a neurotoxin around a cancer acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze cancer cells through efferent channels leaving the cancer vicinity to distant sites. Also, the application of the toxin at sites distant from the cancer enhances cellular and humoral immunologic functions which further contributes to cancer cell death and spread. Following administration of botulinum toxin around and distant to a cancer, it is noticed that local, regional, and distant spread is reduced or eliminated. Immunomodulation with botulinum toxin is also valuable in treating other disease that may or may not be associated with cancers, such as viral-induced growths, viral conditions, fungal disease, chronic wounds, graft versus host disease, autoimmune disease, and HIV.
Inventor(s):	Shaari; Christopher (Demarest, NJ)
Assignee:	Toxcure, Inc. (Demarest, NJ)
Application Number:	12/725,955
Patent Claims:	1. A method of inhibiting the growth or metastases of a neoplasm in a patient, comprising (a) applying to the non-cancerous area around said neoplasm a therapeutically effective amount of botulinum toxin such that the therapeutically effective amount of the botulinum toxin reduces the spread of cells from the neoplasm, and (b) injecting into a regional or distal lymph node or nodes, regional or distal nodal tissue, thymus, spleen or bone marrow of the patient a therapeutically effective amount of botulinum toxin, thereby inhibiting the growth or metastases of the neoplasm. 2. The method of claim 1, wherein the botulinum toxin is botulinum toxin type A or type B. 3. The method of claim 1, wherein the botulinum toxin minimizes and/or stops lymphatic flow in the region outside of the neoplasm. 4. The method of claim 1, wherein the neoplasm is selected from the group consisting of: digestive/intestinal, nervous system, heptobiliary, genitourinary, breast, respiratory, integument, musculoskeletal, hematopoietic, sensory organ, endocrine, and neuroendocrine neoplasms. 5. The method of claim 1, wherein the botulinum toxin is applied topically or by injection in (a). 6. The method of claim 5, wherein the botulinum toxin is applied by injection in (a). 7. The method of claim 2, wherein the botulinum toxin is botulinum toxin type A. 8. The method of claim 2, wherein the botulinum toxin is botulinum toxin type B.

Details for Patent 8,435,951

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2024-09-23